

Diff-Stat™ – Making a *difference*


97% of Residents taking Diff-Stat™ while on Antibiotics did not develop AAD & 100% did not develop C-diff!

Incidence of AAD



- 97% had no AAD
- 3% developed AAD

Incidence of C-diff



- 100% had no C-diff
- 0% developed C-diff

ABSTRACT

Objective:

To assess the efficacy of a synbiotic chewable tablet (Diff-Stat) in preventing AAD & C-diff in residents on antibiotic therapy.

Design:

A multi-state, multi-center observational trial.
Setting: 17 LTC facilities.
Subjects: 93 residents (29 male and 64 female).
77% had no history of C-diff.

Methods:

Subjects on antibiotic therapy were given 1 chewable tablet bid within 3 days of starting antibiotics for the duration of antibiotic therapy and continued for 2 weeks post therapy. Clinicians completed a questionnaire evaluating the product.

Results:

A total of 93 subjects completed the trial.

Primary outcome:

97% (90/93) of residents did not develop AAD for up to 2 weeks post antibiotic therapy.
100% (93/93) of residents did not develop C-diff for up to 2 weeks post antibiotic therapy.

Secondary outcome:

99% (92/93) of clinicians indicated that Diff-Stat was easy to administer.
91% (85/93) of residents had "good" compliance to Diff-Stat.
0% (0/93) of residents had "poor" compliance to Diff-Stat.
99% (92/93) of residents indicated that the taste was acceptable.

Conclusion:

This survey provides support on the potential efficacy of Diff-Stat in helping to prevent AAD and C-diff in residents taking antibiotics, and demonstrates acceptance, tolerability, and ease of administration.

